19Indexed trials
mesh condition
Tobacco Use Disorder
Intelligence
Tobacco Use Disorder intelligence: 19 indexed trials, 3 recruiting studies, 17 sponsors across 4 countries.
3Recruiting
17Sponsors
4Countries
Leading sponsors
Massachusetts General Hospital21 recruiting
University of California, Los Angeles21 recruiting
Duke University10 recruiting
Lisa Sanderson Cox, PhD10 recruiting
Mark Vander Weg10 recruiting
Medical University of South Carolina10 recruiting
Northwestern University10 recruiting
Sahlgrenska University Hospital10 recruiting
Sigmund Freud PrivatUniversitat11 recruiting
University of California, San Francisco10 recruiting
University of Colorado, Denver10 recruiting
University of Missouri-Columbia10 recruiting
Geographic activity
United States15trials
Austria1trials
Canada1trials
Sweden1trials
Leading interventions
Varenicline3trials
Bupropion2trials
Transcranial Magnetic Stimulation2trials
Alcohol use risk reduction1trials
Behavioral management of postcessation weight gain1trials
Behavioral activation for depressive symptoms1trials
Combination pharmacotherapy - Transdermal nicotine patch + bupropion1trials
Cannabidiol (CBD) 800 mg1trials
Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum1trials
Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge1trials
Continuous Theta-burst stimulation (cTBS)1trials
BASC1trials
Methodology note
This entity is derived from structured ClinicalTrials.gov conditions and/or MeSH normalization. Counts reflect the current NeuroRisk indexed corpus and are not guaranteed exhaustive global totals.